Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 2/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.35 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.35 |
| ▸ | METAP1 | P53582 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL972753 | 0.77 | CCNT1 (0.38) | — | |
| SCHEMBL4494048 | 0.76 | GSK3B (0.42) | GSK3BDYRK1AATRNAMPTCYP17A1 | |
| SCHEMBL30594003 | 0.75 | RAB9A (0.54) | NAMPT | |
| SCHEMBL30832555 | 0.75 | GSK3B (0.46) | GSK3BDYRK1AATRNAMPTCYP17A1 | |
| SCHEMBL29008076 | 0.75 | MAPKAPK2 (0.46) | GSK3BDYRK1AATRNAMPTCYP17A1 | |
| SCHEMBL1475335 | 0.75 | RAB9A (0.54) | NAMPT | |
| SCHEMBL1932040 | 0.75 | GSK3B (0.46) | GSK3BDYRK1AATRNAMPTCYP17A1 | |
| SCHEMBL22259406 | 0.74 | GSK3B (0.43) | GSK3BDYRK1AATRNAMPTCYP17A1 | |
| SCHEMBL29498375 | 0.74 | GSK3B (0.43) | GSK3BDYRK1AATRNAMPTCYP17A1 | |
| SCHEMBL4988646 | 0.74 | NAMPT (0.49) | ATRNAMPTCYP17A1CA1MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131113-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | HOFFMANN-LA ROCHE INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-8258134-B2 | Pyridazinone glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-8178689-B2 | Tricyclic compounds | HOFFMAN-LA ROCHE INC. (US) | 2012-05-15 | — | — | US | disclosed |
| EP-2274297-B1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2012-05-09 | — | — | EP | disclosed |
| US-20110313002-A1 | TRICYCLIC COMPOUNDS | SARABU RAMAKANTH (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110021570-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | HAYNES NANCY-ELLEN | 2011-01-27 | — | — | US | disclosed |
| EP-2274297-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | F. Hoffmann-La Roche AG (CH) | 2011-01-19 | — | — | EP | disclosed |
| US-7741327-B2 | Pyrrolidinone glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20090264445-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2009-10-22 | — | — | US | disclosed |
| US-20090264434-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2009-10-22 | — | — | US | disclosed |
| WO-2009127546-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131113-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | GCK, PDXK, G6PD | GSK3B 1884/4885DYRK1A 1056/4885ATR 4005/4885 |
| US-20090264445-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | GCKR, GCK, PDK2 | GSK3B 2528/4885DYRK1A 1278/4885ATR 4060/4885 |
| US-20110021570-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | GCK, PDXK, G6PD | GSK3B 1884/4885DYRK1A 1056/4885ATR 4005/4885 |
| US-20090264434-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | GCK, GCKR, PDXK | GSK3B 1999/4885DYRK1A 985/4885ATR 4284/4885 |
| US-20110313002-A1 | TRICYCLIC COMPOUNDS | GPR119, PC, GOT2 | GSK3B 2138/4885DYRK1A 4339/4885ATR 4427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.